Frontlight ResearchEarly access
Childhood cancers trials in Netherlands
96 of 121 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1CompletedStudy of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
- Where
- Groningen
- Age
- 12 years and over
- People
- 464 worldwide
- Run by
- Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00 - Phase 1Not yet taking people in NetherlandsLong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- Where
- Amsterdam
- People
- 12 worldwide
- Run by
- USWM Ct LLC
See details and how to join2024-513033-21-00 - Phase 1/2CompletedA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Utrecht
- Age
- 6 months to 17 years
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - Phase 1/2Taking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Utrecht
- Age
- 1 year to 17 years
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Utrecht
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 3Taking peopleA Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Where
- Utrecht
- Age
- 1 year to 64 years
- People
- 130 worldwide
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00 - Phase 1/2Taking peopleSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Where
- Utrecht
- Age
- 1 year to 30 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07387926 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Utrecht
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Utrecht
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 2/3Taking peopleA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- Where
- Amsterdam, Nieuwegein, Nijmegen, Rotterdam, Utrecht
- Age
- 12 years and over
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00 - Phase 2Taking people177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
- Where
- Utrecht
- Age
- 18 months to 64 years
- People
- 24 worldwide
- Run by
- Jakob Stenman
See details and how to joinNCT04903899 · EU 2023-503684-42-00 - Phase 1/2Taking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Amsterdam, Groningen
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - Phase 1/2Taking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - Phase 2/3Taking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Amsterdam, Maastricht, Nijmegen, Rotterdam, Utrecht
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Utrecht
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1/2Taking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Utrecht
- Age
- 1 month to 17 years
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - Phase 3Taking peopleInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Utrecht
- Age
- 1 year to 64 years
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - Phase 3Not yet taking people in NetherlandsFight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
- Where
- Groningen, Leiden, Nijmegen, Utrecht
- Age
- 4 years and over
- People
- 530 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864 - Phase 3Taking peopleInternational study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
- Where
- Utrecht
- Age
- Up to 17 years
- People
- 137 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501454-11-00 - Phase 2Taking peopleINTERACT Stomach-II
- Where
- Amsterdam, Eindhoven, Rotterdam
- People
- 55
- Run by
- Erasmus Medical Center
See details and how to joinNCT07133490 · EU 2025-521468-36-00 - Phase 3Not yet taking people in NetherlandsComparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
- Where
- Utrecht
- Age
- Up to 5 years
- People
- 96 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT07291102 · EU 2024-517133-40-00 - Phase 3Taking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Utrecht
- Age
- 1 day to 1 year
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - Phase 3Taking peopleTeicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
- Where
- Utrecht
- Age
- Up to 64 years
- People
- 128 worldwide
- Run by
- Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 - Phase 1/2Active, not recruitingA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Where
- Utrecht
- Age
- 30 days and over
- People
- 447 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00 - Phase 1Taking peopleZiftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
- Where
- Utrecht
- Age
- 0 years to 21 years
- People
- 20 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00